Devimistat
Devimistat tried to starve pancreatic cancer cells of their energy supply alongside chemotherapy; the phase 3 AVENGER 500 trial found no survival gain.
Overview
Devimistat (CPI-613) was developed by Rafael Pharmaceuticals, later renamed Cornerstone Pharmaceuticals, as a first-in-class drug against cancer cell metabolism. Early trials combined it with modified FOLFIRINOX in metastatic pancreatic cancer with encouraging response rates.
The phase 3 AVENGER 500 trial randomised patients with untreated metastatic pancreatic adenocarcinoma to modified FOLFIRINOX with or without devimistat. It did not improve overall survival, and a parallel phase 3 in acute myeloid leukaemia (ARMADA 2000) also missed. Development in pancreatic cancer stopped.
A lipoate analogue that disrupts the tumour's mitochondrial energy metabolism by inhibiting pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase.
1.Devimistat slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Devimistat" OR ABSTRACT:"Devimistat" OR TITLE:"CPI-613" OR ABSTRACT:"CPI-613") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Devimistat, not a curated reading list.